- Home
- VOR vs CRBP Comparison
VOR vs CRBP Comparison
Compare VOR & CRBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VOR
- CRBP
- Stock Information
- Founded
- VOR 2015
- CRBP 2009
- Country
- VOR United States
- CRBP United States
- Employees
- VOR N/A
- CRBP N/A
- Industry
- VOR Biotechnology: Pharmaceutical Preparations
- CRBP Biotechnology: Pharmaceutical Preparations
- Sector
- VOR Health Care
- CRBP Health Care
- Exchange
- VOR Nasdaq
- CRBP Nasdaq
- Market Cap
- VOR 85.7M
- CRBP 73.4M
- IPO Year
- VOR 2021
- CRBP N/A
- Fundamental
- Price
- VOR $0.15
- CRBP $6.45
- Analyst Decision
- VOR Buy
- CRBP Strong Buy
- Analyst Count
- VOR 7
- CRBP 10
- Target Price
- VOR $7.83
- CRBP $53.56
- AVG Volume (30 Days)
- VOR 1.2M
- CRBP 147.8K
- Earning Date
- VOR 05-20-2025
- CRBP 05-06-2025
- Dividend Yield
- VOR N/A
- CRBP N/A
- EPS Growth
- VOR N/A
- CRBP N/A
- EPS
- VOR N/A
- CRBP N/A
- Revenue
- VOR N/A
- CRBP N/A
- Revenue This Year
- VOR N/A
- CRBP N/A
- Revenue Next Year
- VOR N/A
- CRBP $150.00
- P/E Ratio
- VOR N/A
- CRBP N/A
- Revenue Growth
- VOR N/A
- CRBP N/A
- 52 Week Low
- VOR $0.15
- CRBP $4.64
- 52 Week High
- VOR $1.87
- CRBP $61.90
- Technical
- Relative Strength Index (RSI)
- VOR 14.55
- CRBP 46.87
- Support Level
- VOR $0.65
- CRBP $6.10
- Resistance Level
- VOR $0.85
- CRBP $8.07
- Average True Range (ATR)
- VOR 0.07
- CRBP 0.71
- MACD
- VOR -0.05
- CRBP -0.10
- Stochastic Oscillator
- VOR 2.67
- CRBP 13.31
About VOR Vor Biopharma Inc.
Vor Biopharma Inc is a clinical stage cell therapy company. It combines a novel patient engineering approach with targeted therapies to provide a solution for patients suffering from hematological malignancies. The company's products include VCAR33, Tremcel and Myelodysplastic Syndrome, Trem-cel+VCAR33 Treatment System, VADC45, CD123, CLL1, EMR2.
About CRBP Corbus Pharmaceuticals Holdings Inc.
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.